This is a Trial of MG1-E6E7 With Ad-E6E7 and Atezolizumab in Patients With HPV Associated Cancers

Exclusion Criteria

• •Prior systemic therapy within 4 weeks.
• •Patients receiving prior XRT must have recovered from any acute toxicity.
• •Currently receiving/received experimental therapy within 4 weeks.
• •Prior treatment with any HPV vaccine therapy for cancer.
• •Requires use of anti-platelet or anti-coagulant therapy that cannot be safely suspended for per protocol biopsies or intra-tumoral injections.
• •Known active CNS metastases and/or carcinomatous meningitis.
• •Clinically significant tumor invasion/ rapidly accumulating ascites, pericardial or pleural effusions.
• •Active infection requiring systemic therapy.
• •Active autoimmune disease that has required systemic therapy in the past 2 years.
• •Conditions likely to have resulted in splenic dysfunction.
• •Known HIV/AIDS, active HBV or HCV infection.
• •Received prior treatment with vesicular stomatitis (VSV) viral vector.
• •Received immunosuppressive medication within 4 weeks. (\>10mg/day prednisone)
• •≥ Grade 2 dyspnea and/or require supplemental oxygen
• •Known intolerance to anti-PD-1 or anti-PD-L1 antibody therapy
• •Patients with household contacts meeting any of the following criteria are ineligible for study entry unless alternate living arrangements can be made, while under contact precautions.
• •Women who are pregnant or nursing an infant
• •Children \< 1 year old
• •Individuals who are severely immunocompromised
• •Contact precautions are from initial treatment with MG1-E6E7 to 7 days after the last dose of MG1-E6E7